Cadrenal Therapeutics Inc... (CVKD)
NASDAQ: CVKD
· Real-Time Price · USD
12.60
-0.32 (-2.48%)
At close: Aug 15, 2025, 3:59 PM
12.69
0.71%
After-hours: Aug 15, 2025, 06:19 PM EDT
Cadrenal Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | 2.13K | 2.13K | 2.13K | 2.77K | 2.77K | 2.77K | 2.77K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 7.39K | 7.46K | 2.54K | 2.07K | 2.26K | 2.39K | 1.98K | 2.14K | 2.05K | 1.46K | 1.27K | 506.00 | n/a | n/a |
Gross Profit | -5.26K | -5.33K | -407 | 697.00 | 507.00 | 380.00 | 787.00 | -2.14K | -2.05K | -1.46K | -1.27K | -506 | n/a | n/a |
Operating Income | -14.4M | -13.13M | -10.96M | -7.95M | -6.63M | -5.19M | -7.63M | -7.44M | -7.28M | -6.73M | -2.7M | -1.63M | -654.41K | -172.06K |
Interest Income | 292.89K | 299.52K | 309.25K | 337.86K | 391.88K | 341.42K | 249.09K | 129.32K | 23.18K | 3.00 | 3.00 | 3.00 | n/a | n/a |
Pretax Income | -14.11M | -12.83M | -10.65M | -7.61M | -6.24M | -4.85M | -8.36M | -12.22M | -12.21M | -11.71M | -6.71M | -1.7M | -678.79K | -176.65K |
Net Income | -10.44M | -12.83M | -10.65M | -7.61M | -6.24M | -4.85M | -8.36M | -12.22M | -12.23M | -11.73M | -6.74M | -1.73M | -680.33K | -178.19K |
Selling & General & Admin | 9.33M | 7.88M | 6.75M | 4.92M | 4.14M | 3.71M | 3.55M | 3.61M | 3.62M | 3.12M | 2.31M | 1.35M | 432.77K | 152.66K |
Research & Development | 5.07M | 5.24M | 4.21M | 3.03M | 2.49M | 1.48M | 4.08M | 3.84M | 3.65M | 3.61M | 392.86K | 276.48K | 220.09K | 17.86K |
Other Expenses | 1.22K | 1.28K | 1.88K | 2.07K | 2.26K | 2.39K | 1.98K | 878.00 | 787.00 | 190.00 | n/a | 506.00 | n/a | n/a |
Operating Expenses | 14.4M | 13.13M | 10.96M | 7.94M | 6.63M | 5.19M | 7.63M | 7.44M | 7.27M | 6.73M | 2.7M | 1.63M | 652.87K | 170.52K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 17.1K | 72.84K | 104.85K | 119.62K | 107.11K | 51.37K | 19.36K | 4.59K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -389.84K | -389.84K | -389.84K | -389.84K | n/a | n/a | n/a |
Cost & Expenses | 14.4M | 13.13M | 10.96M | 7.95M | 6.63M | 5.19M | 7.63M | 7.44M | 7.28M | 6.73M | 2.7M | 1.63M | 652.87K | 170.52K |
Income Tax Expense | n/a | n/a | 3.00 | 6.00 | 6.00 | 6.00 | 3.00 | -22.85K | -1.54K | -1.54K | n/a | 22.85K | 1.54K | 1.54K |
Shares Outstanding (Basic) | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M | 11.63M | 11.63M |
Shares Outstanding (Diluted) | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M | 11.63M | 11.63M |
EPS (Basic) | -8.89 | -9.26 | -8.72 | -7.29 | -6.3 | -5.34 | -10.41 | -15.55 | -14.45 | -13.21 | -6.61 | -0.15 | -0.06 | -0.02 |
EPS (Diluted) | -8.89 | -9.26 | -8.72 | -7.29 | -6.3 | -5.34 | -10.41 | -15.55 | -14.45 | -13.21 | -6.61 | -0.15 | -0.06 | -0.02 |
EBITDA | -14.17M | -12.83M | -10.65M | -7.61M | -6.23M | -4.84M | -8.34M | -12.15M | -12.11M | -11.59M | -6.6M | -1.65M | -654.41K | -172.06K |
EBIT | -14.11M | -12.83M | -10.65M | -7.61M | -6.24M | -4.85M | -8.34M | -12.15M | -12.11M | -11.59M | -6.61M | -1.65M | -659.43K | -172.06K |
Depreciation & Amortization | 6.73K | 6.8K | 1.88K | 2.07K | 2.26K | 2.39K | 1.98K | 2.14K | 2.05K | 87.52K | 88.87K | 88.11K | 87.6K | 1.54K |